Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TIL therapy in advanced hepatobiliary-pancreatic cancers
NCT05098197Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in hepatobiliary cancer (HBC) and pancreatic cancer (PC), sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 6 months, Objective Response Rate at 36 months and 4 more. Started Sep 2021; status: recruiting.
02
Conditions
hepatobiliary cancer (HBC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05098197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098197.